TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01768091

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: POEM
Description: 1. Entry to submucosal space. After submucosal injection, a 2-cm longitudinal mucosal incision is made at approximately 13 cm proximal to the gastroesophageal junction (GEJ).~2. Submucosal tunnelling. A long submucosal tunnel is created to 3 cm distal to the GEJ.~3. Endoscopic myotomy is begun at 3 cm distal to the mucosal entry point, and is carried out in a proximal to distal direction to a total length of 10 cm.~4. Long endoscopic myotomy of inner circular muscle bundles is done, leaving the outer longitudinal muscle layer intact. The expected end point of myotomy is 2 cm distal to the GEJ.~5. Closure of mucosal entry: the mucosal incision is closed using hemostatic clips.~(Inoue H et al. POEM for esophageal achalasia... Endoscopy 2010; 42: 265-271)

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Pneumatic dilation
Description: A Rigiflex balloon (30 mm) was positioned at the esophagogastric junction and dilated at a pressure of 5 PSI for 1 minute, followed by 8 PSI for 1 minute.~(N Engl J Med 2011;364:1807-16.)
Study: NCT04373642

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pebrolizumab + QUADSHOT Radiotherapy
Description: Treatment will consist of QUAD SHOT radiotherapy combined with pembrolizumab.
Study: NCT01179789

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Optimal Diet
Description: a dietician will train each subject (or the caregiver) to use the personalized diet on web platform

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: VSL#3®
Description: probiotic blend Product should be administrated orally, 2 capsules b.i.d. on an empty stomach (at least 30 min. before lunch and dinner) with a glass of water

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: AISA-5203-L
Description: fruit extracted terpene Product should be administrated orally, the dosage depending from the body weight of the subject enrolled in the study as already stated : 1-2 pills three times a day with a meal and a large glass of water

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Argan oil
Description: Product should be administrated orally, 25 ml once daily or during the day with a meal (bread, salad ...) and a large glass of water
Study: NCT01361113

Intervention type: DRUG
Group type: OTHER
Intervention: Pazopanib
Description: 800 mg orally once daily for 8 weeks, prior to nephrectomy
Study: NCT02548923

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexmedetomidine
Description: comparison to propofol
Study: NCT00894244

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Radiofrequency device
Description: One treatment pass on one arm. 2-5 treatment passes on the other
Study: NCT01237327

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Megestrol acetate
Description: Megestrol Acetate 160 mg oral tablets Qd

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: exemestane (Aromasin)
Description: exemestane (Aromasin) 25 mg oral tablets Qd
Study: NCT03205098

Intervention type: BIOLOGICAL
Intervention: Blood analysis
Description: Blood test of biological markers of mesenteric ischemia
Study: NCT00070213

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: FOLFOX regimen

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FOLFOX regimen

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: capecitabine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: capecitabine

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: fluorouracil

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fluorouracil

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: leucovorin calcium

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: leucovorin calcium

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: oxaliplatin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: oxaliplatin

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: quality-of-life assessment

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: quality-of-life assessment

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: quality-of-life assessment

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: quality-of-life assessment
Study: NCT00106639

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CP-690,550
Description: 15 mg twice daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CP-690,550
Description: 30 mg twice daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: tacrolimus
Description: dose adjusted according to level
Study: NCT02769936

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: D-cycloserine
Description: 100 mg D-cycloserine administered orally as encapsulated pill

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: D-cycloserine
Description: 100 mg D-cycloserine administered orally as encapsulated pill

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo administered orally as encapsulated pill

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo administered orally as encapsulated pill
Study: NCT03296020

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: HONEY
Description: 100% Natural pure Honey, produced by EIN HAROD CO-OPERATIVE, ISRAEL
Study: NCT03013608

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Simple relocation of the nail plate in nailbed injuries in paediatric population
Description: Repositioning the nail bed without sutures
Study: NCT03933722

Intervention type: DEVICE
Intervention: Caretaker
Description: Application of Caretaker device to subjects that have septic shock and that have an invasive arterial pressure monitor placed.
Study: NCT03941197

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Ready and Healthy for Kindergarten Family Literacy program
Description: Participants will participate in 8 parent-child health-themed literacy workshops. Participants will receive 2-3 text messages per week for 8 weeks.
Study: NCT00752869

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: dutasteride
Description: 0.5mg by mouth one time per day for 1 year

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: one tablet per day for 1 year
Study: NCT02919007

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Silk'n HST treatment
Description: Intervention includes treatment with the Silk'n HST on the periorbital areas as instructed in the user's manual
Study: NCT04108949

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Tuning in to Kids
Description: A psychosocial intervention focusing on emotion socialization and emotion coaching.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Treatment as usual
Description: See description included in arm/Group description.
Study: NCT00701480

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: skin cleanser contained Hibiscus sabdariffa extract
Description: face washing 2-3 times/day

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: marketed skin cleanser
Description: face washing 2-3 times/day
Study: NCT03468452

Intervention type: OTHER
Intervention: extubation
Description: Time of extubation

Intervention type: OTHER
Intervention: extubation
Description: Time of extubation
Study: NCT04065581

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acarbose/Metformin FDC(BAY81-9783)
Description: Single dose: 50 mg acarbose/500 mg metformin tablet, oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acarbose/Metformin FDC(BAY81-9783)
Description: Single dose: 50 mg acarbose/500 mg metformin tablet, oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glucobay
Description: Single dose: 50 mg tablet, oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glucobay
Description: Single dose: 50 mg tablet, oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glucophage
Description: Single dose: 500 mg tablet, oral
Study: NCT00258362

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carboplatin
Description: Dose = Area-under-the-curve 6 on Day 1 every 3 weeks for 3 cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: docetaxel
Description: 75 mg/m\^2 on Day 1 of each course

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiation therapy
Description: Weekly, 5 days/week over 6-7 weeks (tailored 4500 cGy)
Study: NCT02869815

Intervention type: PROCEDURE
Intervention: ICG+Methylene Blue
Description: ICG+Methylene Blue Arm:~One ml of methylene blue (1%) would be in injected sub-areolarly 5 minutes before surgery, and 1ml of ICG (0.125%) in the same site 3 minutes later. Massage of the breast would be applied to facilitate the movement of the tracers. A small incision would be made in the axilla, and a special device would be used to search the light nodes. During the sampling, blue nodes would also be resected . After the completion of SLNB, complete axillary dissection would be carried out.
Study: NCT01458080

Intervention type: DRUG
Intervention: eltrombopag
Description: eltrombopag
Study: NCT02721433

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pamidronate
Description: Bone-targeted agent as standard of care

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pamidronate
Description: Bone-targeted agent as standard of care

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Denosumab
Description: Bone-targeted agent as standard of care

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Denosumab
Description: Bone-targeted agent as standard of care

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Zoledronate
Description: Bone-targeted agent as standard of care

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Zoledronate
Description: Bone-targeted agent as standard of care
Study: NCT04036253

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Erythropoietin alfa
Description: Prefilled syringes of erythropoietin
Study: NCT04065581

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glucophage
Description: Single dose: 500 mg tablet, oral
Study: NCT01994902

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Coloplast test product
Description: The Coloplast test product is a newly developed ostomy appliance

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Coloplast test product
Description: The Coloplast test product is a newly developed ostomy appliance

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SenSura Convex Light
Description: The comparator product is SenSura Convex Light, which is CE-marked and commercially available.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SenSura Convex Light
Description: The comparator product is SenSura Convex Light, which is CE-marked and commercially available.
Study: NCT01256385

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Cetuximab
Description: Given IV
Study: NCT04036253

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Erythropoietin alfa
Description: Prefilled syringes of erythropoietin
Study: NCT03068793

Intervention type: DIAGNOSTIC_TEST
Intervention: Electroencephalography (EEG) and Magnetic Resonance Imaging (MRI)
Description: We will use these techniques combined with tests of reward anticipation and clinical interviews to explore connections between these measures and activity in the brain in patients with a diagnosis of schizophrenia, major depressive disorder, gambling disorder, or post traumatic stress disorder and healthy controls.

Intervention type: DIAGNOSTIC_TEST
Intervention: Electroencephalography (EEG) and Magnetic Resonance Imaging (MRI)
Description: We will use these techniques combined with tests of reward anticipation and clinical interviews to explore connections between these measures and activity in the brain in patients with a diagnosis of schizophrenia, major depressive disorder, gambling disorder, or post traumatic stress disorder and healthy controls.

Intervention type: DIAGNOSTIC_TEST
Intervention: Electroencephalography (EEG) and Magnetic Resonance Imaging (MRI)
Description: We will use these techniques combined with tests of reward anticipation and clinical interviews to explore connections between these measures and activity in the brain in patients with a diagnosis of schizophrenia, major depressive disorder, gambling disorder, or post traumatic stress disorder and healthy controls.

Intervention type: DIAGNOSTIC_TEST
Intervention: Electroencephalography (EEG) and Magnetic Resonance Imaging (MRI)
Description: We will use these techniques combined with tests of reward anticipation and clinical interviews to explore connections between these measures and activity in the brain in patients with a diagnosis of schizophrenia, major depressive disorder, gambling disorder, or post traumatic stress disorder and healthy controls.

Intervention type: DIAGNOSTIC_TEST
Intervention: Electroencephalography (EEG) and Magnetic Resonance Imaging (MRI)
Description: We will use these techniques combined with tests of reward anticipation and clinical interviews to explore connections between these measures and activity in the brain in patients with a diagnosis of schizophrenia, major depressive disorder, gambling disorder, or post traumatic stress disorder and healthy controls.
Study: NCT00870532

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: oral vinorelbine
Description: The patients will be divided into 3 cohorts (15 patients per cohort), each cohort receiving a fixed metronomic (thrice a week) dose of oral vinorelbine at 60 mg/week, 90 mg/week, and 120 mg/week respectively. We should arrive at 3 different MTDs from the 3 cohorts.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: oral vinorelbine
Description: The patients will be divided into 3 cohorts (15 patients per cohort), each cohort receiving a fixed metronomic (thrice a week) dose of oral vinorelbine at 60 mg/week, 90 mg/week, and 120 mg/week respectively. We should arrive at 3 different MTDs from the 3 cohorts.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: oral vinorelbine
Description: The patients will be divided into 3 cohorts (15 patients per cohort), each cohort receiving a fixed metronomic (thrice a week) dose of oral vinorelbine at 60 mg/week, 90 mg/week, and 120 mg/week respectively. We should arrive at 3 different MTDs from the 3 cohorts.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sorafenib
Description: Each patient within each cohort will receive a starting dose of sorafenib at 200 mg bid for 4 weeks. In the absence of dose-limiting toxicities, the dose of sorafenib will be escalated to 400 mg bid for another 4 weeks, 600 mg bid for 4 weeks and then finally 800 mg bid. We should arrive at 3 different MTDs from the 3 cohorts.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sorafenib
Description: Each patient within each cohort will receive a starting dose of sorafenib at 200 mg bid for 4 weeks. In the absence of dose-limiting toxicities, the dose of sorafenib will be escalated to 400 mg bid for another 4 weeks, 600 mg bid for 4 weeks and then finally 800 mg bid. We should arrive at 3 different MTDs from the 3 cohorts.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sorafenib
Description: Each patient within each cohort will receive a starting dose of sorafenib at 200 mg bid for 4 weeks. In the absence of dose-limiting toxicities, the dose of sorafenib will be escalated to 400 mg bid for another 4 weeks, 600 mg bid for 4 weeks and then finally 800 mg bid. We should arrive at 3 different MTDs from the 3 cohorts.
Study: NCT00917462

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sorafenib, administered orally
Description: Sorafenib 400 mg twice daily administered continuously. Patients will continue on treatment until progression of disease. Each cycle consists of 28 days. The cycle start date will coincide with the physician visit date. Because of the potential need for physician visit scheduling to vary (due to both physician and patient issues), to avoid violation of, and deviation from, the protocol, these visits may vary by up to one to fourteen (1-14) days. A study diary will be completed by patients to ensure compliance with the study drug.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: CT/MRI
Description: A CT (computerized tomography) or MRI (magnetic resonance imaging) scan of the chest and abdomen will be obtained at baseline, after the first four weeks of therapy, at eight weeks, and then every eight weeks there afterwith a scheduling window of up to one to fourteen (1-14) days. The same imaging modality performed at baseline (CT or MRI) will be repeated at subsequent imaging.
Study: NCT02176382

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: denosumab
Description: denosumab subcutaneous injection

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: denosumab
Description: denosumab subcutaneous injection

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: teriparatide
Description: teriparatide daily subcutaneous injection

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: teriparatide
Description: teriparatide daily subcutaneous injection

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Zoledronic acid
Description: zoledronic acid infusion

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Zoledronic acid
Description: zoledronic acid infusion
Study: NCT01256385

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temsirolimus
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temsirolimus
Description: Given IV
Study: NCT02897063

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Droxidopa
Description: Single oral dose 300 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midodrine
Description: Single oral dose 10 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: sugar pill

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: sugar pill
Study: NCT03631654

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ivabradine
Description: Ivabradine administration--tablets given 5 mg twice daily for 2 weeks, then 7.5 mg twice daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebos
Description: Placebo
Study: NCT03215407

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intra-articular Tocilizumab
Description: Patients will be randomly chosen to be intra-articular injected of tocilizumab injection

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intra-articular Compound Betamethasone
Description: Patients will be randomly chosen to be intra-articular injected of compound betamethasone injection
Study: NCT02243046

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Control toothpaste
Description: 1450 ppm fluoride toothpaste control - Subjects will brush their whole mouth with the control toothpaste 2 times/day for 1 minute each time and rinse with water after brushing. This daily brushing routine will continue for the six (6) month study.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Experimental toothpaste
Description: 1450 ppm sodium fluoride/zinc base toothpaste - Subjects will brush their whole mouth with a fluoride/zinc toothpaste 2 times/day for 1 minute each time and rinse with water after brushing. This daily brushing routine will continue for the six (6) month study.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Active Comparator
Description: 1450 ppm sodium fluoride/triclosan toothpaste - Subjects will brush their whole mouth with this toothpaste 2 times/day for 1 minute each time and rinse with water after brushing. This daily brushing routine will continue for the six (6) month study.
Study: NCT04170244

Intervention type: OTHER
Intervention: AD subject visit sampling procedures
Description: Skin swabs for microbial analysis, Tape stripping and transepidermal water loss measurements (TEWL) with tape stripping (all patients) to assess skin barrier function, blood serum (adults \& optional for adolescents), and optional biopsy (adults only)

Intervention type: OTHER
Intervention: PS subject visit sampling procedures
Description: Skin swabs for microbial analysis, Tape stripping and transepidermal water loss measurements (TEWL) with tape stripping (all patients) to assess skin barrier function, and blood serum (optional for all PS subjects)

Intervention type: OTHER
Intervention: Healthy control visit sampling procedures
Description: Skin swabs for microbial analysis, Tape stripping and transepidermal water loss measurements (TEWL) with tape stripping (all patients) to assess skin barrier function, blood serum (adults \& optional for adolescents), and optional biopsy (adults only)
Study: NCT01342172

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: Patients will receive gemcitabine 1000 mg/m2 IV on days 1 + 8 and cisplatin 70 mg/m2 IV on day 1 of each 21 day cycle. Lenalidomide will be given orally on days 1-14 and the dose will be escalated in successive cohorts during the phase Ib portion to define the recommended phase II dose. Patients will continue gemcitabine, cisplatin, plus lenalidomide for up to 6 cycles, in the absence of disease progression or prohibitive toxicity. After completion of 6 cycles of therapy, patients who have achieved at least stable disease will proceed with maintenance lenalidomide given orally on days 1-21 of each 28-day cycle. Treatment will continue, in the absence of prohibitive toxicity, until the time of disease progression.
Study: NCT04246645

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: CORE STABILITY EXERCISES
Description: SELECTED CORE EXERCISES
Study: NCT01303640

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Biolimus-eluting stent
Description: Biolimus-eluting stent

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Everolimus-eluting stent
Description: Everolimus-eluting stent
Study: NCT03704116

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Expedition
Description: On a laptop computer participants work on simulated daily life activities including packing for a trip, navigating a transit system, and learning at museum attractions. The intervention increases difficulty as participants accomplish goals. We are testing the effects of this performance challenge on executive function measures.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Expedition
Description: On a laptop computer participants work on simulated daily life activities including packing for a trip, navigating a transit system, and learning at museum attractions. The intervention increases difficulty as participants accomplish goals. We are testing the effects of this performance challenge on executive function measures.
Study: NCT02616718

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Repeated computed tomography scan of abdomen
Description: Repeated computed tomography scan of abdomen within two weeks prior to surgery or 28-32 weeks after initial scan